Effects of sample handling methods on substance P concentrations and immunoreactivity in bovine blood samples by Mosher, Ruby A. et al.
Statistics Publications Statistics
2014
Effects of sample handling methods on substance P
concentrations and immunoreactivity in bovine
blood samples
Ruby A. Mosher
Kansas State University
Johann F. Coetzee
Kansas State University
Portia S. Allen
Kansas State University
James A. Havel
PharmCATS Bioanalytical Services
Gary R. Griffith
PharmCATS Bioanalytical Services
See next page for additional authors
Follow this and additional works at: http://lib.dr.iastate.edu/stat_las_pubs
Part of the L rge or Food Animal and Equine Medicine Commons, Statistical Methodology
Commons, Veterinary Microbiology and Immunobiology Commons, and the Veterinary Physiology
Commons
The complete bibliographic information for this item can be found at http://lib.dr.iastate.edu/
stat_las_pubs/87. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html.
This Article is brought to you for free and open access by the Statistics at Iowa State University Digital Repository. It has been accepted for inclusion in
Statistics Publications by an authorized administrator of Iowa State University Digital Repository. For more information, please contact
digirep@iastate.edu.
Effects of sample handling methods on substance P concentrations and
immunoreactivity in bovine blood samples
Abstract
Objective—To determine the effects of protease inhibitors and holding times and temperatures before
processing on the stability of substance P in bovine blood samples.
Samples—Blood samples obtained from a healthy 6-month-old calf.
Procedures—Blood samples were dispensed into tubes containing exogenous substance P and 1 of 6
degradative enzyme inhibitor treatments: heparin, EDTA, EDTA with 1 of 2 concentrations of aprotinin, or
EDTA with 1 of 2 concentrations of a commercially available protease inhibitor cocktail. Plasma was
harvested immediately following collection or after 1, 3, 6, 12, or 24 hours of holding at ambient (20.3° to
25.4°C) or ice bath temperatures. Total substance P immunoreactivity was determined with an ELISA;
concentrations of the substance P parent molecule, a metabolite composed of the 9 terminal amino acids, and
a metabolite composed of the 5 terminal amino acids were determined with liquid chromatography–tandem
mass spectrometry.
Results—Regarding blood samples processed immediately, no significant differences in substance P
concentrations or immunoreactivity were detected among enzyme inhibitor treatments. In blood samples
processed at 1 hour of holding, substance P parent molecule concentration was significantly lower for ambient
temperature versus ice bath temperature holding conditions; aprotinin was the most effective inhibitor of
substance P degradation at the ice bath temperature. The ELISA substance P immunoreactivity was typically
lower for blood samples with heparin versus samples with other inhibitors processed at 1 hour of holding in
either temperature condition.
Conclusions and Clinical Relevance—Results suggested that blood samples should be chilled and plasma
harvested within 1 hour after collection to prevent substance P degradation.
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Objective—To determine the effects of protease inhibitors and holding times and tempera-
tures before processing on the stability of substance P in bovine blood samples.
Samples—Blood samples obtained from a healthy 6-month-old calf.
Procedures—Blood samples were dispensed into tubes containing exogenous substance 
P and 1 of 6 degradative enzyme inhibitor treatments: heparin, EDTA, EDTA with 1 of 2 
concentrations of aprotinin, or EDTA with 1 of 2 concentrations of a commercially available 
protease inhibitor cocktail. Plasma was harvested immediately following collection or after 
1, 3, 6, 12, or 24 hours of holding at ambient (20.3° to 25.4°C) or ice bath temperatures. 
Total substance P immunoreactivity was determined with an ELISA; concentrations of the 
substance P parent molecule, a metabolite composed of the 9 terminal amino acids, and a 
metabolite composed of the 5 terminal amino acids were determined with liquid chroma-
tography–tandem mass spectrometry.
Results—Regarding blood samples processed immediately, no significant differences in 
substance P concentrations or immunoreactivity were detected among enzyme inhibitor 
treatments. In blood samples processed at 1 hour of holding, substance P parent molecule 
concentration was significantly lower for ambient temperature versus ice bath temperature 
holding conditions; aprotinin was the most effective inhibitor of substance P degradation 
at the ice bath temperature. The ELISA substance P immunoreactivity was typically lower 
for blood samples with heparin versus samples with other inhibitors processed at 1 hour of 
holding in either temperature condition.
Conclusions and Clinical Relevance—Results suggested that blood samples should be 
chilled and plasma harvested within 1 hour after collection to prevent substance P degrada-
tion. (Am J Vet Res 2014;75:109–116)
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Because of societal concerns for the welfare of farm animals, various organizations have implemented or 
are considering the implementation of regulations con-
cerning painful husbandry procedures such as dehorn-
ing and castration.1 To provide proper scientific evi-
dence for regulatory decisions and for the development 
of pain-mitigating options, there is a need for studies 
in which pain-relieving techniques for food animal 
species are investigated. A major impediment to deter-
mination of conclusions from such studies is the lack 
of an objective measure of pain in animals. Circulat-
ing cortisol concentration has been used as a response 
variable to estimate the severity of noxious stimulation 
attributable to procedures in various studies, but that 
method has limitations.2 Substance P concentration has 
ABBREVIATIONS
KIU  Kallikrein inhibitor units
LC-MS-MS  Liquid chromatography–tandem 
   mass spectrometry
SP
1–11 
Parent substance P molecule   
   composed of 11 amino acids
SP
3–11
  Metabolite of substance P composed 
   of the last 9 C-terminal amino acids
SP
7–11
  Metabolite of substance P composed 
   of the last 5 C-terminal amino acids
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been evaluated as a response variable that may be more 
specific for the measurement of pain in animals.3–10
Substance P is a biologically active peptide that has 
a role in neural transmission of nociceptive signals from 
peripheral sites to the CNS.11 Substance P is released by 
peptidergic peripheral sensory nerve fibers at central 
synaptic junctions in the dorsal horn of the spinal cord 
and at peripheral nerve terminals, where the peptide 
has a role as a signaling molecule in the transmission of 
pain impulses and the induction of inflammation and 
central sensitization.12
Substance P is a member of the tachykinin fam-
ily and is synthesized in cell bodies from transcripts 
of the gene preprotachykinin-A. The substance P par-
ent molecule is a peptide composed of 11 amino acids 
with an amidated carboxyl terminus (arginine-proline- 
lysine-proline-glutamine-glutamine-phenylalanine-
phenylalanine-glysine-leucine-ethionine-NH
2
). 
Enzymes that cleave SP1–11 include members of the ser-
ine and metalloprotease families: angiotensin I–con-
verting enzyme, aminopeptidase, neutral endopepti-
dase, dipeptidyl peptidase IV, and postproline cleaving 
enzyme.13,14 Enzymes of these classes require inhibitors 
with specific affinity for their catalytic sites; therefore, 
protection of SP1–11 from enzymatic degradation may 
require at least 2 inhibitor types. Various degradation 
products are derived from SP1–11 and are named in accor-
dance with the amino acids they contain. For example, 
cleavage of SP1–11 between the number 2 and number 3 
amino acids (proline and lysine) results in the formation 
of 2 fragments: an arginine-proline fragment and SP3–11. 
Fragments containing the 5 C-terminal amino acids 
(fragments SP7–11 through SP1–11) have similar biological 
effects, although the potency of such effects decreases 
with fewer amino acids.15 Fragments composed of the 
hydrophobic C-terminal and those composed of the 
hydrophilic N-terminal have opposite biological effects. 
Results of another study16 suggest that the antinocicep-
tive effects of morphine are enhanced when combined 
with the substance P fragment composed of the first 7 
amino acids. Knowledge of the fragmentation profile of 
substance P may therefore increase understanding of 
pain processing and perception in animals.
Concentrations of substance P can be measured 
by means of ELISA or LC-MS-MS. Whereas concentra-
tions of the substance P parent molecule are specifically 
measured with LC-MS-MS, ELISA measures substance 
P immunoreactivity that includes SP
1–11
, C-terminal 
fragments, and other related immunoreactive peptides. 
In studies involving livestock, sample handling 
conditions are not always ideal. Barns often are dis-
tant from laboratory facilities, and refrigeration or ice 
may not be available for chilling samples. Furthermore, 
samples may be kept in batches for transport to a labo-
ratory where processing is delayed.
In support of research that may use substance P 
concentration or immunoreactivity as a response vari-
able, the purpose of the study reported here was to 
determine the effects of various sample handling tech-
niques on substance P values in blood samples when 
analyzed by means of LC-MS-MS or ELISA. An objec-
tive was to compare the effects of various handling pro-
cedures on concentrations of SP
1–11
, SP
3–11
, and SP
7–11
 
as measured with LC-MS-MS and on total immunore-
activity of substance P (ie, immunoreactivity of SP
1–11
, 
metabolites of substance P, and other related immuno-
reactive molecules) as measured with ELISA. Another 
objective was to determine the effects of delayed blood 
sample processing (up to 24 hours) and the tempera-
ture (ambient or ice bath) at which a sample was kept 
during that period. In addition, 2 concentrations of the 
enzyme inhibitor aprotinin in EDTA, 2 concentrations 
of a commercially marketed complete protease inhibi-
tor cocktailin EDTA, EDTA alone, and heparin were 
compared with respect to protection of SP1–11 and total 
immunoreactivity of substance P from degradation.
Materials and Methods
Samples—Blood samples collected from a healthy 
6-month-old Holstein calf were used in the study. All 
experimental procedures in this study were approved 
by the Kansas State University Institutional Animal 
Care and Use Committee under the supervision of the 
university veterinarian.
Collection tube preparation—Enzyme inhibi-
tor treatments were prepared and added to tubes ap-
proximately 8 hours prior to blood sample collection. 
Aprotinin powder was dissolved and serially diluted 
with deionized water to create 2 stock solutions that 
would provide final concentrations of 50 and 500 KIU/
mL when diluted in the collected blood samples as rec-
ommended by manufacturers of the ELISA kita used for 
determination of total substance P immunoreactivity 
in this study. A commercially available protease inhibi-
tor cocktail tabletb was dissolved and serially diluted 
in deionized water in accordance with the manufac-
turer’s recommendations to provide solutions of single 
strength and double strength when diluted in blood 
samples. To prepare tubes containing aprotinin or com-
plete protease inhibitor cocktail, 100 µL of a concen-
trated stock solution was added to an uncapped 4-mL 
blood collection tube containing K
3
EDTA. All tubes 
were recapped and refrigerated (4°C) overnight.
Approximately 1 hour prior to blood sample col-
lection, a spiking solution of SP1–11 was prepared by 
adding 1 mL of 0.1% formic acid to a vial containing 
425,000 ng of SP1–11. From this solution, serial dilutions 
were made with 0.1% formic acid to obtain a solution 
containing SP1–11 at a concentration of 50 ng/mL. Fifty 
microliters of the SP
1–11
 solution was added to each of 
the prepared tubes containing enzyme inhibitors, lithi-
um heparin, or K
3
EDTA alone to provide a final concen-
tration of 625 pg/mL when mixed with 4 mL of whole 
blood.
The blood sample collection tubes were arranged 
in 3 replicate arrays for each blood sample holding pe-
riod (0, 1, 3, 6, 12, and 24 hours of holding before pro-
cessing). The arrays to be used for holding periods of 
1, 3, 6, 12, and 24 hours each contained 2 sets (1 for 
each temperature treatment [ambient and ice bath tem-
peratures]) of the following 6 enzyme inhibitor treat-
ments spiked with 625 pg/mL of SP
1–11
: heparin (15 U/
mL; USP standard), EDTA (1.8 mg/mL), aprotinin (50 
or 500 KIU/mL) combined with EDTA (1.8 mg/mL), or 
protease inhibitor cocktail (single strength or double 
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strength) combined with EDTA (1.8 mg/mL). Arrays to 
be used for immediate processing (0 hours of holding) 
contained only 1 set of the 6 inhibitor treatments be-
cause there was no temperature treatment. In addition 
to the tubes with enzyme inhibitor treatments, each ar-
ray also contained 1 tube containing double-strength 
protease inhibitor cocktail that was not spiked with 
SP
1–11
; contents of this tube were to be processed im-
mediately to detect endogenous concentrations of sub-
stance P. For samples in the tube containing double-
strength protease inhibitor cocktail that was not spiked 
with SP
1–11
, it was assumed a priori that this inhibitor 
cocktail would provide the fullest extent of protection 
against the various types of enzymes that degrade sub-
stance P. All tubes were then kept in a cooler filled with 
crushed ice for transport to the barn facility for blood 
sample collection.
Blood sample collection—Whole blood (total 
volume, 864 mL) was obtained from the calf. Approxi-
mately 18 hours prior to blood sample collection, the 
calf was restrained in a chute and an indwelling jugular 
venous catheter was placed with local anesthesia. To 
maintain patency overnight, the catheter was flushed 
once with 3 mL of a 3 U/mL heparin solution (heparin 
sodiumc diluted with saline [0.9% NaCl] solutionc; USP 
standard).
On the morning of blood sample collection, the 
calf was restrained in a chute while the tubes in 3 ar-
rays were uncapped in preparation for filling of the first 
blood sample collection series. The heparin solution 
was cleared from the catheter by attaching a syringe 
and, in 3 repetitions, drawing 5 mL of blood into the sy-
ringe, then depressing the plunger to return the blood 
into the jugular vein of the calf. A collection series con-
sisted of 3 syringes of blood and was performed as fol-
lows. A 60-mL syringe was attached to the uncapped 
catheter and filled during 30 to 60 seconds, after which 
4 mL of blood was rapidly transferred to each of the 13 
tubes in the first array. As soon as a tube was filled, it 
was recapped and rapidly inverted 10 times to ensure 
thorough mixing of the contents. During this time, an-
other 60-mL syringe was attached to the catheter and 
the next blood sample collection was performed. After 
the filling of tubes in each array was completed (time, 
approx 1 minute), the tubes were immediately placed in 
their holding environment and the start time and tem-
perature were recorded. In this manner, the process was 
repeated to quickly obtain 3 complete replicate treat-
ment arrays for each holding period. To facilitate the 
processing of samples, the order of collection for each 
holding period was as follows: 12-, 6-, 3-, 24-, 0-, and 
then 1-hour periods. Collection and processing of the 
blood samples for the 3 arrays in each holding period 
was completed in a mean ± SD time of 5 ± 2 minutes. 
Approximately 5 minutes was needed between collec-
tion of blood samples for each array to prepare for the 
next blood sample collection series, resulting in a mean 
± SD time of 11 ± 2 minutes between times that blood 
sample collection was started for each collection series.
Blood samples for ambient temperature holding 
were placed in a test tube rack, whereas samples for 
chilled holding were immediately plunged into a bath of 
crushed ice in an insulated portable cooler. For chilled 
blood samples, care was taken to ensure that only the 
cap and a small amount of each tube remained above 
the ice surface. Ambient temperature was recorded with 
a digital thermometer placed on the benchtop near the 
samples. Temperature in the cooler at the ice-air in-
terface was recorded with a similar thermometer that 
was protected in a plastic bag. Ambient temperatures 
ranged from 20.3° to 21.2°C during the 1-hour sample 
collection period at the barn, then ranged from 23.9° to 
25.4°C during the remaining 24-hour holding period 
in the laboratory. The temperature of the ice bath–air 
interface in the cooler ranged from 4.5° to 7.3°C during 
the 1-hour period during blood sample collection and 
ranged from 0.1° to 2.2°C during the remaining holding 
period in the laboratory; however, the blood samples in 
those tubes were kept below the ice surface, where the 
presumed temperature at the ice-water interface was 
0°C.
Blood samples were either processed within 5 min-
utes after collection (0 hours) or kept for 1, 3, 6, 12, or 
24 hours prior to processing. During processing, blood 
samples were centrifuged in a refrigerated unit (4°C) at 
10,000 X g for 15 minutes. Tubes were then removed 
from the centrifuge and kept in an ice bath while plas-
ma was harvested and divided among paired cryovials 
(2 aliquots); plasma samples were kept at –70°C until 
analysis. The 0-hour blood samples spiked with SP
1–11
 
and the samples in tubes with double-strength protease 
inhibitor cocktail that were not spiked with SP1–11 were 
processed in the barn with the same refrigerated centri-
fuge that was used to process the other blood samples. 
For holding periods processed in the barn, cryovials 
with harvested plasma were immediately placed in a 
cooler on ice packs (which had been kept overnight at 
–70°C); these plasma samples were then transported to 
the laboratory, where they were observed to have frozen 
during the < 10-minute transit. These plasma samples 
were kept at –70°C until analysis. Blood samples for all 
other holding periods were processed in the laboratory, 
with care taken to ensure that they were handled in a 
manner similar to samples that were processed in the 
barn.
LC-MS-MS analysis of SP
1–11
 and metabolite con-
centrations—Only samples for 0-, 1-, 3-, and 6-hour 
holding periods were analyzed by means of LC-MS-MS. 
Analysis of 1 aliquot of the plasma samples was per-
formed within 6 weeks after collection and storage at 
–70°C.
An LC-MS-MS method was used for the analysis 
of concentrations of SP1–11, SP3–11, and SP7–11 in plas-
ma samples. A structurally related peptide, [Tyr8]-
substance P, was used as the internal standard for all 
analytes. The analytes and internal standard were iso-
lated from 0.5 mL of each aliquot of plasma samples 
by means of solid-phase extraction with hydrophilic, 
lipophilic balanced cartridges. Extracts were evaporated 
until dry and reconstituted in the starting mobile phase. 
Electrospray ionization and tandem mass spectrometry 
were performed with a high-performance liquid chro-
matography system coupled with a triple quadrupole 
mass spectrometer.d Chromatographic separation of all 
analytes and internal standard was achieved with an 
analytic columne and a gradient elution from 100% of 
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one mobile phase (0.2% acetic acid in water) to 80% of 
another mobile phase (0.2% acetic acid in acetonitrile) 
and re-equilibration during a runtime of 15.0 minutes. 
This method was accurate and precise for a linear dy-
namic range from the lower limit of quantitation (50 
pg/mL) to 1,000 pg/mL (data not shown).
ELISA analysis of total immunoreactivity of sub-
stance P—Approximately 18 months after blood sam-
ple collection and plasma sample storage at –70°C, an 
aliquot of plasma samples for all holding periods from 
0 to 24 hours were analyzed for determination of to-
tal immunoreactivity of substance P with a validated 
ELISA method.3 Briefly, analytes were extracted from 
plasma by acidification with acetic acid and fractionat-
ing with reverse-phase, solid-phase extraction columns. 
Peptides were eluted from the column with an organic 
aqueous solvent mixture and concentrated by drying in 
gaseous nitrogen. The dried extract was reconstituted 
and analyzed in duplicate in accordance with the man-
ufacturer’s instructions for the substance P ELISA kit.a 
Assay performance was monitored with 5 replicates of 
bovine plasma samples containing 0, 200, or 800 pg/
mL of substance P purified standard. The 
method was linear for the 5 replicates of 
each concentration (R2 > 0.99), and the co-
efficient of variation for each concentration 
within an assay run was < 15%. The coef-
ficient of variation for the 5 ELISA runs in 
the study was 42% for 0 pg/mL samples, 
20% for 200 pg/mL samples, and 35% for 
800 pg/mL samples. This ELISAa had the 
following cross-reactivities between the as-
say and metabolites: Sp
1–11
 (100%), SP3-11 
(87.9%), the fragment composed of the 8 
terminal amino acids (11.7%), and SP
7–11
 
(5.9%).
Statistical analysis—Because the 3 
syringes of blood obtained for each col-
lection series were not independent and 
because holding period was confounded 
with collection series, we refrained from 
investigating rates of decay and from 
making comparisons across holding peri-
ods. Instead, we confined our analysis to 
comparisons of the 3 replicates of time 
and temperature combinations within 
each holding period. Furthermore, be-
cause the analyses of samples by means of 
LC-MS-MS and ELISA were not performed 
after the same freezer storage time and be-
cause the ELISA method cross-reacted with 
substance P metabolites, we also refrained 
from statistical comparison of total immu-
noreactivity of substance P (determined 
with ELISA) with a summary measure of 
SP
1–11
, SP
3–11
, and SP
7–11
 concentrations (de-
termined with LC-MS-MS).
The response variables of SP
1–11
, 
SP
3–11
, and SP
7–11
 concentrations and total 
immunoreactivity of substance P were 
transformed (natural log) and analyzed 
with ANOVA models. For graphic presen-
tation, the means and 95% confidence intervals were 
transformed back to the original units. Fixed effects 
included temperature (ice bath holding conditions vs 
ambient temperature holding conditions) and enzyme 
inhibitor (aprotinin [50 or 500 KIU/mL] in EDTA, pro-
tease inhibitor cocktail [single or double strength] in 
EDTA, EDTA alone, and heparin). For analyses of total 
immunoreactivity of substance P, the ELISA run num-
ber was used as a random effect. Differences among 
treatment groups were assessed on the basis of results 
of Tukey pairwise t tests by time. Data analyses were 
performed with statistical software.f Values of P ≤ 0.05 
were considered significant.
Results 
Analysis of blood samples that were not spiked 
with SP1–11—For blood samples with double-strength 
protease inhibitor cocktail that were not spiked with 
SP
1–11 
and were processed immediately following col-
lection, results of LC-MS-MS analysis indicated no de-
tectable concentrations of endogenous SP1–11, SP3–11, or 
SP7–11. In such samples analyzed by means of ELISA, the 
Figure 1—Back-transformed least squares median concentration estimates and up-
per 95% confidence intervals of LC-MS-MS assay total concentrations of SP
1–11
 in 
blood samples collected from a 6-month-old calf, spiked with 625 pg of SP
1–11
/mL, 
mixed with various enzyme inhibitors, and processed immediately (gray bars; A) or 
after 1 (B), 3 (C), or 6 (D) hours of holding at ambient (20.3° to 25.4°C; black bars) or 
ice bath (white bars) temperatures. The enzyme inhibitors included heparin (15 U/
mL; HEP), EDTA (1.8 mg/mL), aprotinin (50 KIU/mL [AP50] or 500 KIU/mL [AP500]) 
combined with EDTA (1.8 mg/mL), or a protease inhibitor cocktail (tablet dissolved 
and diluted in deionized water to provide concentrations of single strength [TAB1X] 
or double strength [TAB2X]) combined with EDTA (1.8 mg/mL). Processing included 
centrifugation and harvesting of plasma. *Sample had no detectable analyte or a 
peak concentration less than the lower limit of quantitation of the assay. a–gWithin 
each holding period, values without a common letter are significantly (P < 0.05) 
different.
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amount of immunoreactivity was similar to that for refer-
ence samples containing 0 pg of substance P standard/mL.
LC-MS-MS analysis of blood samples spiked with 
SP
1–11
—Results of LC-MS-MS analysis regarding ex 
vivo degradation of SP1–11, SP3–11, and SP7–11 indicated 
the main effects of holding temperature and enzyme 
inhibitor were significant (P < 0.001). Although there 
was significant (P < 0.001) interaction between holding 
temperature and enzyme inhibitor for SP
3–11
 and SP
7–11
, 
interaction between those variables was not significant 
(P = 0.06) for SP
1–11
. Concentrations of SP
1–11
 (Figure 
1), SP
3–11
 (Figure 2), and SP
7–11
 (Figure 3) were sum-
marized. For blood samples processed immediately 
following collection (0 hours of holding), there were 
no significant (P > 0.12) differences in concentrations 
of SP
1–11
, SP
3–11
, or SP
7–11
 among the enzyme inhibitor 
treatments.
Within 1-, 3-, or 6-hour holding periods, SP
1–11
 con-
centrations in blood samples kept in an ice bath were 
significantly (P < 0.005) greater than concentrations in 
blood samples kept at ambient temperature. For blood 
samples kept in an ice bath for 1 hour prior to process-
ing, the only significant differences in SP
1–11
 concentra-
tions were between samples with either concentration 
of aprotinin (50 or 500 KIU/mL) and samples with oth-
er enzyme inhibitors. The SP
1–11
 concentration in blood 
samples with 500 KIU of aprotinin/mL was significantly 
(P < 0.018) greater than the concentrations in samples 
with heparin or single- or double-strength protease 
inhibitor cocktail. The SP
1–11
 concentrations in blood 
samples with 50 KIU of aprotinin/mL were significantly 
(P < 0.04) greater than they were in samples with hepa-
rin or double-strength protease inhibitor cocktail. For 
blood samples kept in an ice bath for 1 hour prior to 
processing, there were no significant (P > 0.99) differ-
ences in SP
1–11
 concentration between samples with ei-
ther concentration of aprotinin (50 or 500 KIU/mL) or 
between samples with either concentration of protease 
inhibitor cocktail (single or double strength).
ELISA analysis of blood samples spiked with 
SP
1–11
—Results of ELISAs regarding total immunoreac-
tivity of substance P for all holding periods (0 to 24 
hours) were summarized (Figure 4). The interaction 
between holding temperature and enzyme inhibitor 
was significant (P < 0.001).
For blood samples that were processed immediate-
ly after collection, there were no significant (P > 0.93) 
differences in total immunoreactivity of substance P 
among the enzyme inhibitor treatments. Within the 1- 
and 3-hour holding periods for ice bath and ambient 
temperature holding conditions, there were no signifi-
cant (P > 0.92) differences in total immunoreactivity 
of substance P among samples treated with either con-
centration of aprotinin, either concentration of pro-
tease inhibitor cocktail, and EDTA alone. Within the 
1-hour holding period, the total immunoreactivity of 
substance P in blood samples treated with heparin was 
significantly (P < 0.001) lower than that in samples 
treated with any other enzyme inhibitor for ambient 
temperature holding conditions and significantly (P < 
0.04) lower than that in samples treated with 50 KIU 
of aprotinin/mL or double-strength protease inhibitor 
cocktail for ice bath holding conditions.
Although not statistically compared, total 
immunoreactivity of substance P as measured with 
Figure 2—Back-transformed least squares median concentration 
estimates and upper 95% confidence intervals of LC-MS-MS 
assay total concentrations of SP3–11 in blood samples collected 
from a 6-month-old calf, spiked with 625 pg of SP
1–11
/mL, mixed 
with various enzyme inhibitors, and processed immediately (gray 
bars; A) or after 1 (B) or 3 (C) hours of holding at ambient (20.3° to 
25.4°C; black bars) or ice bath (white bars) temperatures. Data for 
the 6-hour holding time are not shown because no analyte peaks 
were detected in those samples. a–eWithin each holding period, 
values without a common letter are significantly (P < 0.05) differ-
ent. See Figure 1 for remainder of key.
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ELISA seemed to increase in blood samples kept > 3 
hours prior to processing. The immunoreactivity in 
blood samples kept 6 and 24 hours prior to processing 
was similar to that in samples that were immediately 
processed (0 hours of holding). Within each enzyme 
inhibitor group in ice bath holding conditions, the to-
tal immunoreactivity of substance P as measured with 
ELISA seemed to be lower at 12 hours than it was at 6 
and 24 hours of holding before processing.
Discussion
In the present study, we investigated the effects of 
various enzyme inhibitor types and holding times and 
temperatures on substance P concentrations as deter-
mined by means of LC-MS-MS and ELISA. Because 
there is variation among animals regarding stress re-
sponses and chemical, enzymatic, and cellular compo-
nents of blood and because it was not possible to collect 
and pool whole blood samples from several animals, 
only 1 animal was used in the study. This was meant to 
control for those potential sources of variability, which 
might have obscured differences among groups. The 
animal used in this study was a healthy randomly se-
lected calf and was considered to be representative of 
other calves; therefore, the use of blood samples from 
only 1 calf was not thought to have affected inferences 
made on the basis of the results of the study. Further-
more, because blood components may 
vary over time within an individual and 
because analyses for each holding peri-
od were performed with blood samples 
obtained at a distinct time, we refrained 
from making inferences for results be-
tween holding periods (because differ-
ences might have been caused by intra-
individual variation).
As suggested by results that indi-
cated approximately equal concentra-
tions of SP1–11 and SP3–11 in the 0-hour 
blood samples analyzed by means of 
LC-MS-MS, there seemed to be rapid 
early cleavage of SP
1–11
 to SP
3–11
, which 
was found for all enzyme treatments. 
Immediately after blood samples were 
added to the test tubes, there was a short 
period during the tube inversion process 
before the inhibitors were homogenous-
ly mixed with blood samples; during this 
time, enzymes in blood samples may 
have been able to act freely on SP1–11. 
This source of substance P degradation 
might have been minimized by spiking 
the tubes with exogenous substance P 
after, rather than before, the addition of 
whole blood; however, the intent of the 
study was to evaluate substance P deg-
radation attributable to handling pro-
cedures, as would occur when SP1–11 is 
present in circulating blood. Given that 
inhibitor molecules may be dissociated 
from the protease enzymes, a portion of 
the enzymatic cleavage of SP
1–11
 to SP
3–11
 
could also have occurred during the 
15-minute centrifugation, the 5- to 10-minute period 
of plasma sample harvest, the storage period at –70°C, 
and the thaw process prior to analysis.
When blood samples were kept at ambient tempera-
ture, enzymatic processes seemed to proceed more rap-
idly than when they were kept in an ice bath. Enzymes 
are typically more active at physiologic temperatures than 
they are at colder temperatures, so these results were not 
unexpected. In samples kept for 1 hour prior to process-
ing, concentrations of SP
1–11
 as determined by means of 
LC-MS-MS were approximately 50% lower in samples 
kept at ambient temperatures than they were in samples 
kept in an ice bath. Even when blood samples were in an 
ice bath, SP
1–11
 concentrations were near the lower limit 
of quantitation when kept for 3 hours prior to process-
ing. Therefore, results of LC-MS-MS analysis of SP
1–11
 
concentrations suggested that blood samples should ei-
ther be processed immediately or kept in an ice bath and 
processed within 1 hour after collection. When blood 
samples were processed immediately, the type of enzyme 
inhibitor did not significantly affect concentrations of 
SP1–11 or SP3–11. When blood samples were kept for 1 hour 
in an ice bath, aprotinin seemed to be the best enzyme 
inhibitor for protection of SP
1–11
 from enzymatic degrada-
tion, and no significant differences were detected between 
the 50 or 500 KIU/mL concentrations of that inhibitor. 
Because the composition of the complete protease inhibi-
Figure 3—Back-transformed least squares median concentration estimates and upper 
95% confidence intervals of LC-MS-MS assay total concentrations of SP7–11 in blood 
samples collected from a 6-month-old calf, spiked with 625 pg of SP
1–11
/mL, mixed 
with various enzyme inhibitors, and processed immediately (gray bars; A) or after 1 
(B), 3 (C), or 6 (D) hours of holding at ambient (20.3° to 25.4°C; black bars) or ice bath 
(white bars) temperatures. a–dWithin each holding period, values without a common 
letter are significantly (P < 0.05) different. See Figure 1 for remainder of key.
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tor cocktail tablet is proprietary information, it was not 
known whether aprotinin was included in that formula-
tion; however, for blood samples kept in an ice bath for 1 
hour prior to processing, neither the single- nor double-
strength concentrations of the cocktail seemed to provide 
more protection of SP
1–11
 than EDTA alone.
Similar to LC-MS-MS analysis results for SP
1–11
 and 
SP
3–11
 concentrations, results of ELISAs for blood samples 
processed immediately indicated the type of enzyme in-
hibitor did not significantly affect total immunoreactiv-
ity of substance P. Unlike the results determined with 
LC-MS-MS, there were no significant effects of tempera-
ture for blood samples kept 1 or 3 hours before process-
ing as determined with ELISA. This was likely because the 
ELISA measured SP
1–11
 and substance P degradation prod-
ucts that had a carboxyl terminus group.
This study may not have had a high enough power 
to detect some differences between treatments as deter-
mined with the ELISA, given the inter- 
assay coefficient of variation of 20% to 35% 
of that assay in a substance P concentra-
tion range of 200 to 800 pg/mL. Although 
the ELISA results seemed to be unaffected 
by holding temperatures for blood sam-
ples, especially for those processed within 
1 hour after collection, it is important to 
recognize that the assay has 100% cross-
reactivity only for SP1–11; therefore, the goal 
of sample handling should be to preserve 
SP
1–11
 so that accurate results are obtained. 
For studies in which a difference in sub-
stance P concentrations between groups is 
the alternate hypothesis, true differences 
between groups might not be detected if 
SP1–11 is unnecessarily allowed to degrade 
to SP
3–11
 and if other metabolites for which 
the percentages of cross-reactivity for the 
ELISA are not as high. Pronounced intra- 
and interindividual variability of plasma 
substance P immunoreactivity has been 
detected for control and castrated calves in 
another study.3 Therefore, it is important 
to control for as much procedure-related 
variability and to measure the highest con-
centrations of the substance P parent mol-
ecule in blood samples as possible so that 
true differences between treatment groups 
are not missed because of artificially low 
substance P immunoreactivity and high 
errors in values.
For both SP
1–11
 concentrations and 
total immunoreactivity of substance P, 
we could not determine whether the 
differences between the 1- and 0-hour 
holding period blood samples were sig-
nificant, although such differences were 
typically large. This suggested that a 
strict processing order should be ad-
hered to; the processing order should 
follow the blood sample collection or-
der, without large discrepancies in the 
amount of time between collection and 
processing. Otherwise, substantial dif-
ferences in results could occur because of sample han-
dling. Alternately, variability in results among samples 
may have been high enough to prevent identification of 
significant differences attributable to treatments.
The finding of low concentrations of SP
1–11
 typi-
cally detected in blood samples after a 3-hour holding 
period supported the recommendation that samples ob-
tained for analysis of substance P should be processed 
within 1 hour following collection. For holding times 
> 3 hours between collection and processing, a factor 
other than enzymatic degradation seemed to affect sub-
stance P concentrations in whole blood samples; the 
ELISA total immunoreactivity of substance P seemed 
to increase after more than 3 hours. Notably, for blood 
samples kept in an ice bath for 24 hours, the ELISA 
total immunoreactivity of substance P was similar to 
that for samples processed immediately following col-
lection, regardless of the type of enzyme inhibitor treat-
Figure 4—Back-transformed least squares median concentration estimates and upper 
95% confidence intervals of ELISA total immunoreactivity of substance P (ie, immu-
noreactivity of SP1–11, metabolites of substance P, and other related immunoreactive 
molecules) in blood samples collected from a 6-month-old calf, spiked with 625 pg 
of SP
1–11
/mL, mixed with various enzyme inhibitors, and processed immediately (gray 
bars; A) or after 1 (B), 3 (C), 6 (D), 12 (E), or 24 (F) hours of holding at ambient (20.3° 
to 25.4°C; black bars) or ice bath (white bars) temperatures. a–fWithin each holding pe-
riod, values without a common letter are significantly (P < 0.05) different. See Figure 
1 for remainder of key.
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ment. The ELISA total immunoreactivity of substance 
P in samples kept 6 and 12 hours before processing 
were typically similar to those for samples kept 0 and 
24 hours before processing, depending on the enzyme 
inhibitor. Similarly, concentrations of SP
1–11
 in blood 
samples kept in an ice bath seemed to increase from 3 
to 6 hours after collection.
The finding of high immunoreactivity of substance 
P in blood samples kept for > 3 hours prior to process-
ing suggested the possibility that substance P (or other 
molecules with cross-reactivity to the ELISA) was being 
produced by cells in the whole blood samples after collec-
tion. Production of substance P in blood samples in vitro 
would not account for the ELISA results that indicate total 
immunoreactivity of substance P at 12 hours of holding 
was typically lower than it was at 6 hours of holding prior 
to processing. This finding might be explained by the or-
der in which the blood samples for each holding period 
were collected. The blood samples in the 12-hour hold-
ing period group were obtained during the first collection 
time. Although the calf was well acclimated to the facility 
and to most of the study personnel, there was more activ-
ity than usual on the day of blood sample collection and 
the animal was unfamiliar with the person collecting the 
samples. Therefore, it was likely that the procedure caused 
stress in the calf. Results of an in vitro study17 of bone mar-
row aspirates of clinically normal humans indicate that 
the addition of ACTH (100 ng/mL) to bone marrow stro-
mal cells induces peak concentrations of substance P at 48 
hours after stimulation. In the present study, it was pos-
sible that the samples collected first (and kept 12 hours 
prior to processing) contained lower concentrations of 
ACTH than those obtained during subsequent collections. 
That possibility might explain the apparent lower ELISA 
total immunoreactivity of substance P detected for blood 
samples kept 12 hours prior to processing versus that for 
samples kept 6 or 24 hours before processing; determi-
nation of ACTH concentrations in blood samples would 
have been necessary to confirm that theory.
Results of this study suggested that various biological 
processes may affect the concentration of substance P fol-
lowing blood sample collection. Thus, to accurately deter-
mine substance P concentrations, blood samples should 
be processed as soon as possible and handled in accor-
dance with a protocol that ensures samples are immediate-
ly chilled to the temperature of an ice bath. Furthermore, 
results suggested it is important that plasma is harvested 
from blood samples in the same order in which samples 
were collected, with similar times between collection 
and harvesting of plasma for all groups. Otherwise, sub-
stantial differences among samples regarding substance 
P concentrations may develop or differences may be ob-
scured because of sample handling techniques. This pro-
cedure is recommended for samples analyzed by means of 
LC-MS-MS or ELISA. Although results of the ELISA in 
this study seemed to be minimally affected by the holding 
temperature during the first hour after blood sample col-
lection, the goal of sample handling should be to preserve 
SP
1–11
, for which that test had the highest percentage of 
cross-reactivity.
Results of this study suggested that use of a standard 
blood collection tube containing heparin or EDTA seemed 
to be as effective for preserving substance P as the com-
bination of EDTA with aprotinin or an enzyme inhibitor 
cocktail, as long as blood samples were chilled and pro-
cessed within 5 minutes after collection. These findings 
were similar for blood samples analyzed by means of 
ELISA and those analyzed by means of LC-MS-MS. 
a. Assay Designs, Enzo Life Sciences Inc, Farmingdale, NY.
b. Complete protease inhibitor tablet, Santa Cruz Biotechnology 
Corp, Santa Cruz, Calif.
c. Baxter Healthcare Corp, Deerfield, Ill.
d. API 4000, AB SCIEX, Framingham, Mass.
e.  XBridge Shield RP18, Waters Corp, Milford, Mass.
f. SAS, version 9.2, SAS Institute Inc, Cary, NC.
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